Study found the Trabectedin-Olaparib combo improves progression-free survival in soft tissue sarcomas with PARP1 expression, suggesting histology-specific benefits.
Although trabectedin-olaparib combination reached the prespecified threshold for statistical significance for PFS (p<0.10), the benefit was marginal in the all-comers STS population. Nonetheless, patients affected by PARP1-expressing STS and uterine leiomyosarcoma derived substantial benefit from the combination, supporting further histology- and biomarker-driven investigation in these settings.
No takes yet. Share an insight, caveat, or question.
D’Ambrosio et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: